Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gli2 shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Gli2 shRNA is a research-stage gene-silencing tool designed to knock down the expression of GLI2 (Glioma-Associated Oncogene 2), a transcription factor and key effector of the Hedgehog (Hh) signaling pathway. GLI2 plays a critical role in cell-fate determination, proliferation, and carcinogenesis by activating genes that inhibit apoptosis and regulate the cell cycle. Preclinical research has utilized Gli2 shRNA to investigate its therapeutic potential in various cancers, including hepatocellular carcinoma (HCC), castration-resistant prostate cancer, cervical cancer, and pancreatic cancer. The tool is typically delivered via lentiviral vectors and is primarily available as a research-use-only (RUO) reagent from suppliers such as Sigma-Aldrich and Santa Cruz Biotechnology.
- Other names
- GLI2 shRNAGLI-2 shRNAGLI 2 shRNAshRNA-Gli2shRNA-Gli-2shRNA-Gli 2Glioma-associated oncogene 2 shRNA
02
Targets
DICER1 (Dicer ribonuclease III)Innate immune RNA sensorsGLI2AGO2 (Argonaute RISC catalytic component 2)
Beyond the preview
Go deeper on Gli2 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gli2 shRNA.